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A b s t r a c t  
Docetaxel is currently used in treatment of breast and ovarian cancers, administered in the form of 
parenteral IV infusion. Lipid nanoemulsion (LNE) delivery system is biocompatible, biodegradable 
and easy to prepare. The aim of this study was to develop stable parenteral pegylated docetaxel 
lipid nanoemulsions (LNEs) for improving cytotoxicity. The O/W LNEs were prepared by 
homogenization and ultrasonication process. The globule sizes and zeta potentials were measured 
by using Malvern Zetasizer.  The sizes of oil globules varied from 70.2 to 243.3 nm and zeta 
potential from î25.5 to î40.2mV. During in vitro drug release studies, the cumulative percentage drug 
released within 15 h from pegylated lipid nanoemulsions, PLNE-3 and PLNE-6 was 84.02μ4.79 and 
88.51μ4.5 respectively. The total drug content and entrapment efficiencies for the prepared LNEs 
were determined by HPLC. The in vitro cell line studies were performed on two cell lines (MCF-7 
and Hela cell lines). When compared to drug solution, PLNE-6 was found to have 1.55 and 1.6 folds 
more cytotoxic activity on MCF-7 and Hela cell lines respectively. The IC 50 values of pegylated 
LNEs on both the cell lines was statistically significant when compared to DS, P<0.05. In conclusion, 
stealth LNEs were prepared, characterized and  found to be stable and superior in delivery of 
docetaxel  to cancer cell lines in comparison to plain LNE and drug solution. 
Keywords: Docetaxel, DSPE-PEG 5000, DPPE-PEG 5000, Stealth Lipid Nanoemulsions, 
cytotoxicity.  
Introduction 
The cancer is second leading cause of mortality after 
cardiovascular disease and accounts for one of every four deaths. 
Docetaxel  is a clinically potent microtubule targeting agent for the 
treatment of cancer[1]. It is a semisynthetic derivative from10-
deacetyl baccatin III, an inactive precursor extracted from the yew 
tree, Taxus baccata. The cytotoxic mechanism of docetaxel 
involves specific covalent binding to assembled tubulin, resulting in 
promotion and stabilization of persistent interphase microtubule 
complexes [2]. It has been approved for use in treatment of six 
different cancer indications, they are locally advanced and 
metastatic breast cancer, non-small cell lung cancer, androgen 
independent prostate cancer, advanced gastric cancer, head and 
neck cancer [3]. Each year, an estimated 3 million patients 
worldwide have been diagnosed with one of these types of cancer.  
Nanomedicine approaches to drug formulation for the treatment of 
solid tumors are reaching clinical application, largely securing 
approval due to improved safety profiles. For example, Doxil® 
(pegylated liposome containing doxorubicin) is an approved 
alternative to conventional doxorubicin for treatment of Kaposi's 
sarcoma, and Abraxane® is an alternative to Taxol® for treatment 
of metastatic breast cancer [4]. Safety enhancements arise due to 
elimination of irritating excipients such as Polysorbate 80 or 
Cremophor (Taxotere and Taxol, respectively) and reduced non-
specific distribution to sensitive tissues (e.g., reduced cardiotoxicity  
with Doxil®).  
The enhanced permeability and retention (EPR) effect in solid 
tumors was first introduced by Matsumura and Maeda [5]. The 
EPR effect can enhance the diffusion of macromolecules or 
nanomedicines into the tumor via leaky tumor vasculature. The 
EPR effect causes increased retention of macromolecules within 
tumor tissues due to the poor tumor lymphatic drainage. EPR is a 
universal phenomenon in solid tumors. 
Todate, various nanoparticles that exhibit the long blood-circulating 
property have been shown to preferentially accumulate in tumors 
due to the leakiness of microvasculature in solid tumors [6]. 
However, the uptake of nanoparticles by macrophages in the 
reticuloendothelial system (RES) should be avoided to achieve an 
efficient EPR effect-based passive targeting of drugs [7]. Various 
strategies, therefore, were developed including the modification of 
the surface of nanoparticles with ganglioside GM1, 
phosphatidylinositol or polyethylene glycol (PEG) [8,9]. Among 
them, the surface modification with PEG (pegylation) is known to 
be a successful strategy. 
ISSN: 0975-0215 
  
This work is licensed under a Creative Commons Attribution 3.0 License.  
Syed et al. International Journal of Drug Delivery 5 (2) 188-195 [2013] 
 
PAGE | 189 |
 
 
Among the various colloidal drug delivery systems, parenteral lipid 
emulsions are commercially available in market for nutrition and 
medicinal purpose. The lipid emulsions (LE) are biocompatible, 
biodegradable and easy to prepare [10].  In LE the lipid core (oil) is 
stabilized by phospholipid monolayer and dispersed in continuous 
aqueous phase. These are, useful in delivering lipophilic drugs, 
mass-produced, easily sterilizable and stable even at room 
temperature for 1ă2 years [11]. 
PEG is a water-soluble, nontoxic, non-antigenic and biocompatible 
polymer, that has been approved by the FDA for human 
intravenous, oral, and dermal applications [12,13]. Attachment of 
PEG (pegylation) to drugs, peptides, proteins, nanoparticles, 
micelles, and liposomes is a mature technology for enhancing the 
bioavailability, stability, safety, and efficacy of a wide range of 
therapeutic agents. Few of the  pegylated products   commercially 
available in the market or in clinical trails are Oncaspar (pegylated 
L- asparaginase), PEGASYS (pegylated  alpha interferon), Cimzia 
(Certolizumab Pegol), Mircera (pegylated form of erythropoietin), 
Neulasta (pegylated recombinant methionyl human granulocyte 
colony-stimulating factor), Adagen: (PEG-adenosine deaminase 
etc. Docetaxel submicron lipid emulsions were reported [14]. There 
is no work regarding the docetaxel being incorporated in pegylated 
emulsions. 
Hence, the objective of this study was to prepare, pegylated lipid 
nanoemulsions (PLNEs) containing docetaxel for parenteral 
intravenous application using biocompatible excipients. We 
investigated the influence of pegylated lipids i.e., 1, 2- distearoyl 
sn- glycero-3-phosphatidylethanolamine (DSPE)-PEG 5000 and 1, 
2- dipalmitoyl sn- glycero-3-phosphatidylethanolamine (DPPE)-
PEG 5000 on in vitro cell lines. Further, formulations were 
characterized, evaluated and cytotoxic activity on two different cell 
lines was compared with Docetaxel solution (DS) and Plain Lipid 
nanoemulsion (LNE).   
Materials and Methods 
Materials 
Purified olive oil (Lipoid, Germany), egg phosphatidyl choline 
(EPC-80) (Lipoid, Germany), cholesterol & glycerol (Merck, 
Mumbai), đ-tocopherol (Sigma, Mumbai), oleic acid (S.D. Fine, 
Mumbai), docetaxel (A kind gift from Dr ReddyÊs Laboratories, 
Hyderabad), DSPE-PEG5000 and DPPE-PEG 5000 (A kind gift 
from Lipoid, Germany) sodium dihydrogen phosphate, disodium 
hydrogen phosphate ( S.D fine Chemicals , Mumbai), centrisort 
tubes (Sartorius, Germany), dialysis membrane ( Hi media, 
Mumbai), chloroform, acetonitrile (Merck., Mumbai). HeLa- Human 
cervical carcinoma cell line (NCCS, Pune), MCF-7 ă Human breast 
carcinoma cell line (NCCS, Pune), RPMI-1640 (Himedia, Mumbai), 
dimethylsulphoxide (DMSO) (Merck India Ltd, Mumbai), SDS lysis 
buffer (Himedia, Mumbai), trypsin (Himedia, Mumbai,), MTT (3-
(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) 
(Himedia, Mumbai). All other chemicals used were of reagent 
grade. 
 
Methods 
Preparation of lipid nanoemulsions (LNE) containing 
docetaxel 
The LNEs were prepared by hot homogenization and 
ultrasonication process and the compositions are shown in Table 1. 
Required quantities of ingredients were weighed. The oil soluble 
substances were added to the oily phase and the water soluble 
substances to the aqueous phase. Then both the phases were 
heated to   70À C.  The aqueous phase was added to oily phase 
slowly drop wise with stirring and then homogenized for about 3 
minutes at 15,000 rpm (Homogenizer Diax 900, Heidolph, 
Germany).  The coarse emulsion was then sonicated (Vibra 
Sonics, Sonics and Materials Inc., USA) for about 20 minutes at 
50% amplitude and characterized for size, polydispersity and zeta 
potential (Zp).   
Determination of globule size, polydispersity index and 
zeta potential   
The mean size and polydispersity index of emulsion globules was 
determined by photon correlation spectroscopy using Zetasizer 
(Malvern Nano ZS90, Malvern, UK). Each sample was diluted to a 
suitable concentration (1 in 50) with filtered double distilled water. 
Analysis was performed at 25 À C with an angle of detection of 90 À. 
During the measurements, average globule count rate was 
maintained between 50 and 500 kcps.  Average of the three 
readings was noted. 
The same sample which was used for size analysis was taken in to 
a dip cell, was then inserted and average of three readings was 
noted by using the instrument Zetasizer (Malvern Nano ZS90, 
Malvern, UK). 
 
Effect of varying concentration of DSPE-PEG 5000 and 
DPPE-PEG 5000 
LNEs were prepared as described above using different 
concentrations of DSPE-PEG 5000 and DPPE-PEG 5000 with   
0.15%, 0.3%, and 0.45% w/v keeping the other ingredients 
constant.  
In vitro drug release studies of LNE formulations 
The drug release was studied by open tube method using 
Cellulose membrane (DM 60 Molecular weight cut off 12000-
14000, Himedia, Mumbai).  Initially, the dialysis membrane was 
hydrated overnight in phosphate buffer pH 7.4 at room 
temperature. The emulsions/solution (1ml) were placed in dialysis 
open tube and then suspended in 100 ml of 30%v/v ethanol 
phosphate buffer pH 7.4 mixture in 250 ml beakers as dialysis 
medium, which was stirred continuously on a magnetic stirrer 
(Remi Equipments, India). At different time intervals i.e., 0.25, 0.5, 
1, 2, 3, 4, 6, 8, 10, and 12 hrs during dialysis, 1 ml of samples were 
withdrawn from the beaker and replaced by equal volume of fresh 
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medium for analyzing the drug content.  The amount of drug in 
collected samples was calculated by using the linear calibration 
curve plotted with known concentrations of drug by measuring the 
absorbance at λmax 227 nm on a UV-Visible spectrophotometer 
(ELICO SL 159, India). The release pattern of the drug from 
different formulations was calculated by plotting cumulative 
percentage drug release vs time. 
 
Stability of LNEs: Effect of centrifugal stress, thermal 
stress, dilution stress and storage 
  
The selected formulations (LNE, PLNE-3 and PLNE-6) were 
studied for the effects of centrifugal stress, thermal stress, dilution 
stress and stability on storage. 
Effect of centrifugal stress on stability  
LNEs of 1ml were filled in eppendorf tubes and were subjected to 
centrifugation (Heraeus Biofuge, Germany) at 13,000 for 10min. 
The creaming volume percentage for each emulsion was 
calculated by using the formula previously reported by Krishna et 
al., 1998 and formulations were compared.  
Effect of autoclaving on the stability of LNEs  
The LNEs were filled into vials and subjected to autoclaving at 
121ÀC for 15 minutes. The formulations were observed for the 
possible changes in particle size, PDI and zeta potentials.  
Effect of Dilution (Desorption Stress) on Stability 
The selected LNEs were diluted with double-distilled water 50 to 
5000 times (1:50, 1:100, 1:200, 1:500, 1:1000 and 1:5000) and the 
effect of dilution on size and Zp was studied using Zeta Sizer.  
Stability of LNEs during storage  
About 1ml of emulsion was filled in eppendorf tubes and was 
stored at 4 ÀC and 25 ÀC for 6 months. At predetermined intervals 
i.e., 0, 1, 2, 3, 4 and 6 months, the samples were analyzed for size, 
polydispersity index and zeta potential. 
 
Determination of total drug content and entrapment  
efficiency 
 
High performance liquid chromatography (HPLC) system 
consisting of a LC-20AD solvent delivery system containing double 
reciprocating plunger pump (Shimadzu, Japan), a SPD-20A  UVă
Visible variable wavelength detector with deuterium lamp 
(Shimadzu), and a 250 x 4.6 mm, 5μ, C-18 reverse phase 
analytical column (Lichospher®, Merck, Mumbai, India) was used 
to determine total drug content and entrapment efficiency of the 
formulations. The mobile phase consisted of 65 parts of acetonitrile 
and 35 parts of double distilled water.  The flow rate was 1 mL/min 
and the detection was performed at λmax of 227nm. 
Drug content 
Each docetaxel loaded LNE (0.1 mL) was diluted to 1mL and 
further diluted twice (1:10) with methanol. The 20μl was injected 
and drug content was determined by the reported HPLC method 
[15]. 
Entrapment efficiency 
Entrapment efficiency (EE) was determined by measuring the 
concentration of free drug (unentrapped) in aqueous medium [16]. 
The aqueous medium was separated by ultra-filtration using 
centrisort tubes (Sartorius, USA), which consisted of filter 
membrane (M.Wt. cut off 20,000 Da) at the base of the sample 
receiver chamber. About 2ml of the formulation was placed in the 
donor chamber and centrifuged at 6500 rpm for 15 min 
(Refrigerated Biofuge). The LNEs along with encapsulated drug 
remained in the donor chamber and aqueous phase moved into the 
receiver chamber through filter membrane. The amount of 
docetaxel in the aqueous phase was estimated by HPLC method 
and the entrapment efficiency was calculated. 
 
In vitro cytotoxic activity by MTT Assay 
The adherent cells (Hela and MCF-7) were trypsinized and were 
resuspended in fresh medium after centrifugation [17]. Cell   
suspension was mixed thoroughly by pippetting several times to 
get a uniform single cell suspension. Different dilutions of drug 
solutions and formulations were made in medium (RPMI-1640) with 
final DMSO concentration in the well to be less than 1%. About 
100μl of cell suspension was transferred aseptically to each well of 
a 96 well plate and to it 100μl of 1% media/ drug solution (n=6) in 
media was added. The plate was then incubated at 37ÀC for 48 
hours in CO2 incubator. After 48 hours of incubation, 20μl of MTT 
was added to each well. The plate was again incubated for 2 
hours. After incubation, 80μl of lysis buffer was added to each well, 
the plate was wrapped in aluminum foil to prevent the oxidation of 
the dye and the plate was placed on a shaker for overnight. The 
absorbances were recorded on the ELISA reader at 562nm 
wavelength. The absorbance of the test was compared with that of 
DMSO control to get the % inhibition. 
Results and Discussion 
Formulation and In vitro release studies 
The lipid nanoemulsions (LNEs) were prepared by hot 
homogenization and ultrasonication process. The initial typical 
formula was selected based on previous literature on parenteral 
lipid emulsions [18]. Plain emulsion LNE consisted of 10% (w/v) 
olive oil as the oil core, 1.2% (w/v) EPC-80 as a phospholipid 
emulsifier, oleic acid (0.3%) as a negative charge inducer, đ-
tocopherol (0.25%) as antioxidant and glycerol (2.25%) (Table 1) 
was added to maintain the isotonicity of the formulation for IV 
administration.    
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Table1: Compositions of the prepared Docetaxel Formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For preparation of pegylated LNEs, DSPE-PEG 5000 or DPPE-
PEG 5000 was incorporated in LNE formulation during the 
preparation. In this study, two pegylated lipids were used at 
different concentrations of 0.15%, 0.3%, 0.45% w/v. The pegylated 
lipids could decrease the size of globules considerably when 
compared to plain emulsion LNE (Table 2). The average size of the 
globules of DSPE-PEG 5000 was slightly less when compared to 
that of DPPE-PEG 5000 and probably this might be due to the 
difference in packing of surfactant molecules in globular surface.  
The percentage drug entrapment of the prepared LNEs was found 
to be excellent and in the range of 97-100% (Table 2). Whereas, 
the drug content was found to be in the range of 9.7 to 10.3 mg 
(Table 2). The drug content was estimated by reported HPLC 
method by using isocratic Shimadzu HPLC. 
 
Table 2: Size, PDI, Zeta potentials, Assay Percentage drug entrapment of the prepared LNEs (n=3).  
Formulation code Size (nm) PDI  Zeta potential(mv) Assay (mg) %Drug entrapment 
 LNE 200.4μ2.3 0.035μ0.21 -35.5μ2.3 10.1μ0.3 97μ0.2 
PLNE-1 115.2μ2.7 0.12μ0.14 -29.9μ1.9 9.8μ0.2 98μ0.1 
PLNE -2 93.4μ1.3 0.051μ0.11 -35μ1.3 9.9μ0.21 99μ0.3 
PLNE -3 70.2μ3.1 0.034μ0.19 -40.2μ1.8 9.8μ0.1 100μ0.1 
PLNE -4 125.4μ1.6 0.017μ0.18 -28.3μ3.2 9.7μ0.21 97μ0.1 
PLNE -5 101.2μ1.9 0.031μ0.11 -29.5μ2.1 9.78μ0.15 98μ0.4 
PLNE -6 83.5μ1.3 0.077μ0.11 -32.4μ1.7 10.2μ0.2 101μ0.3 
 
The In vitro release of LNE after 12 hrs was found to be 96.56μ 
1.79, whereas the in vitro release of the pegylated formulations i.e. 
PLNE-1, PLNE-2, PLNE-3, PLNE -4, PLNE-5 and PLNE-6 after 15 
hrs was found to be 93.99μ1.55, 90.81μ1.53, 84.02μ4.79, 
95.21μ1.45, 91.32μ1.57 and 88.51μ4.5 respectively (fig 1 and 2). 
The in vitro release of the pegylated LNEs was slower than the 
plain emulsion i.e. LNE might be due to the rigidization of the 
membrane at the surface of globules [19]. The In vitro release of 
drug from DSPE-PEG 5000 containing emulsions was relatively 
less than that of the DPPE-PEG 5000 containing emulsions in 
various concentrations. This is probably due to the DSPE moiety 
Formulation 
ingredients  
Plain 
emulsion  
Drug 
Solution 
Varied concentrations of DSPE/DPPE-PEG 5000 
LNE DS PLNE-1 PLNE -2 PLNE -3 PLNE -4 PLNE -5 PLNE -6 
Docetaxel (mg) 10 10 10 10 10 10 10 10 
Olive  oil  (mg) 1000 0 1000 1000 1000 1000 1000 1000 
Egg lecithin (mg) 120 0 120 120 120 120 120 120 
Cholesterol (mg) 30 0 30 30 30 30 30 30 
đ-tocopherol (mg) 25 0 25 25 25 25 25 25 
Oleic acid (mg) 30 0 30 30 30 30 30 30 
DSPE-PEG 5000 (mg) 0 0 15 30 45 0 0 0 
DPPE-PEG 5000(mg) 0 0 0 0 0 15 30 45 
Glycerol (mg) 225 0 225 225 225 225 225 225 
Ethanol (ml) 0 10 0 0 0 0 0 0 
Double distilled water 
to make (ml) 
10  10 10 10 10 10 10 
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Table 4: Effect of autoclaving on size, PDI and zeta potential of selected formulations (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Effect of Dilution (desorption) on size, PDI and zeta 
potentials (n=3). 
 
Stability of parenteral emulsion was mainly studied in terms of 
maintaining of its physical integrity, namely the dispersed phase 
particle size, charge and size distribution on storage at 4ĈC and RT. 
[23]. measured the zeta potential as the indicator for the surface 
potential to evaluate the stability of lipid emulsions. There were no 
appreciable changes in size, Zp and PDI indicating that the LNEs 
were stable on storage (Table 6). 
 
Cytotoxicity 
 
Basing on the results of stability testing and release studies the 
following formulations were selected (LNE, PLNE-3, PLNE-6) for 
the cytotoxicity study on MCF-7 and Hela cell lines. The IC 50 
values were calculated by using the GraphPad Prism software 
(version 5).The IC 50 values on MCF-7 cell lines of LNE, PLNE-3, 
PLNE-6 and DS were found to be 32.31μ1.2 nM , 26.91μ0.8 nM, 
22.97μ1.3 nM and 35.68μ1.9 nM respectively (Table 7) . The IC 50 
values on Hela cell lines of LNE, PLNE-3, PLNE-6, and DS were 
found to be 37.79μ1.12 nM, 31.7μ1.3 nM, 26.13μ1.2 nM and 
41.71μ1.67 nM respectively (Table 7). The IC 50 values of PLNE-3 
when compared to DS, was found to have 1.32 and 1.31 folds 
more cytotoxic activity on MCF-7 and Hela cell lines. Similarly, 
when compared to LNE, PLNE-3 was found to have 1.2 and 1.19 
folds more cytotoxic activity on MCF7 and Hela cell lines 
respectively. The  statistical results of one way ANOVA by 
NewmanăKeuls Multiple comparison test when applied it was 
found that PLNE-3 was statistically  significant with DS and non-
significant with  LNE P<0.05. 
When compared to DS, PLNE-6 was found to have 1.55 and 1.6 
folds more cytotoxic activity on MCF-7 and Hela cell lines. 
Similarly, when compared to LNE, PLNE-6 was found to have 1.4 
and 1.45 folds more cytotoxic activity on MCF-7 and Hela cell lines 
respectively. The  statistical results of one way ANOVA by 
NewmanăKeuls Multiple comparison test when applied,  it was 
found that PLNE-6 was statistically  significant with DS and LNE 
P<0.05. 
 
 
 
Formulation 
code 
Before Sterilization After Sterilization 
Size (nm) PDI Z.P(mV) Size (nm) PDI Z.P(mV) 
LNE 243.30μ5.17 0.05μ0.01 -35.7μ1.91 232.30μ8.0
7 
0.12μ0.03 -33.3μ1.11 
PLNE -3 77.2μ5.05 0.13μ0.05 -
39.83μ0.45 
70.7μ1.39 0.243μ0.14 -36.04μ0.4 
PLNE -6 91.5μ2.36 0.135μ0.1 -
32.16μ0.35 
85.80μ7.36 0.12μ0.11 -27.8μ1.64 
Formulati
on code 
Dilution 
factor 
Size (nm) PDI Zp (mV)
LNE 1:50 243.30μ5.17 0.05μ0.01 -35.7μ1.91
1:100 249.5μ1.63 0.17μ0.2 -34.30μ0.43
1:200 253.5μ4.85 0.25μ0.41 -33.53 μ2.62
1:500 259.47μ5.17 0.29μ0.12 -30.46μ2.41
1:1000 263.2μ3.65 0.30μ0.04 -29.5μ1.53
1:5000 269.5μ1.65 0.29μ0.1 -27.1μ3.34
 
PLNE -3 
1:50 
77.2μ5.05 0.13μ0.05 -39.83μ0.45 
1:100 78.32μ2.68 0.19μ0.04 -38.33μ1.34
1:200 80.43μ3.33 0.13μ0.03 -37.23 μ2.22
1:500 81.24μ4.46 0.17μ0.06 -36.8μ0.15
1:1000 83.3μ3.43 0.21μ0.03 -35.1μ3.54
1:5000 84.6μ2.21 0.23μ0.04 -34.5μ4.34
PLNE -6 1:50 
91.5μ2.36 0.13μ0.1 -32.16μ0.35 
1:100 92.03μ4.34 0.12μ0.02 -31.70μ2.05
1:200 95.17μ3.90 0.19μ0.07 -30.17μ4.31
1:500 96.64μ3.99 0.23μ0.07 -29.04μ3.52
1:1000 97.52μ6.45 0.26μ0.04 -28.30μ4.22
1:5000 99.87μ3.65 0.30μ0.05 -26.0μ5.72
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Table 6: Effect of storage (4ÀC and RT) on stability of LNEs (n=3). 
 
The improved cytotoxicity of pegylated docetaxel LNEs exhibited in 
MTT assay could be attributed to its enhanced uptake because of 
the lowest size and sustained release of the drug. Various studies 
showed that pegylation of the low molecular weight drugs provided 
a sustained release of the drug in the cells due to prolonged 
retention and higher cytotoxicity [24,25].Thus,thein vitro cytotoxicity 
study proved that the pegylated docetaxel LNEs acted more 
effectively in comparison to drug solution in both the cancer cell 
lines, as evident from the lower IC50 values shown in (Table 7). 
  
Table 7: IC 50 values of different optimized docetaxel formulations 
on MCF-7 and Hela cell lines (n=6). 
S. No Formulation 
code 
MCF 7 
(nM) 
Hela 
(nM) 
1 LNE 32.31μ1.2 37.79μ1.12 
2 PLNE-3 26.91μ 0.8** 31.70μ1.3** 
3 PLNE-6 22.97μ 1.3 **,a 26.13μ1.2 **,a 
4 DS 35.68μ1.9 41.71μ1.67 
**Statistically significant with DS (Docetaxel Solution), P<0.05a Statistically 
significant with LNE (Docetaxel  Lipid  Nanoemulsion), P<0.05 
Further, when DSPE-PEG 5000 and DPPE-PEG 5000 are compared, 
DPPE-PEG 5000 is showing relatively greater effect than DSPE-PEG 
5000. 
Conclusion 
Docetaxel lipid nanoemulsions were prepared, characterized and 
the influence of various pegylated lipids was investigated. The 
pegylated lipid nanoemulsions were found to have excellent 
globule size, entrapment efficiency and retarded release of about 
15hrs. Further, in vitro studies on two cell lines clearly indicated to 
have significant cytotoxic activity. In nut shell, these  pegylated 
LNEs would become useful delivery systems in treating cancer. 
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